M
46.10
-0.19 (-0.41%)
| Previous Close | 46.29 |
| Open | 46.00 |
| Volume | 459,783 |
| Avg. Volume (3M) | 634,265 |
| Market Cap | 3,185,071,872 |
| Price / Sales | 79.29 |
| Price / Book | 4.76 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -969.93% |
| Diluted EPS (TTM) | -3.35 |
| Quarterly Revenue Growth (YOY) | 2.20% |
| Total Debt/Equity (MRQ) | 1.53% |
| Current Ratio (MRQ) | 6.53 |
| Operating Cash Flow (TTM) | -185.84 M |
| Levered Free Cash Flow (TTM) | -123.22 M |
| Return on Assets (TTM) | -27.47% |
| Return on Equity (TTM) | -42.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Merus N.V. | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.30 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 2.04% |
| % Held by Institutions | 106.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (Guggenheim, 136.44%) | Buy |
| Median | 84.00 (82.21%) | |
| Low | 70.00 (B of A Securities, 51.84%) | Buy |
| Average | 86.20 (86.99%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 44.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 28 Mar 2025 | 109.00 (136.44%) | Buy | 44.61 |
| 18 Mar 2025 | 109.00 (136.44%) | Buy | 46.39 | |
| B of A Securities | 10 Mar 2025 | 70.00 (51.84%) | Buy | 46.75 |
| HC Wainwright & Co. | 03 Mar 2025 | 85.00 (84.38%) | Buy | 45.47 |
| Needham | 28 Feb 2025 | 83.00 (80.04%) | Buy | 47.09 |
| Piper Sandler | 13 Feb 2025 | 84.00 (82.21%) | Buy | 40.30 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SHUMAN HARRY | - | 47.24 | -4,000 | -188,960 |
| Aggregate Net Quantity | -4,000 | |||
| Aggregate Net Value ($) | -188,960 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 47.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHUMAN HARRY | Officer | 21 Mar 2025 | Sell (-) | 4,000 | 47.24 | 188,960 |
| SHUMAN HARRY | Officer | 21 Mar 2025 | Option execute | 3,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |